PRME - Prime Medicine and Myeloid Therapeutics resolve all pending disputes January, 05 2024 05:10 PM First Trust Heitman Global Prime Real Estate ETF 2024-01-05 17:10:32 ET More on Prime Medicine Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Gene editing stocks gain after Eli Lilly deal amid FDA AdCom For further details see: Prime Medicine and Myeloid Therapeutics resolve all pending disputes